Officers
John D. Irvin, MD, PhD
President and Chairman of the Board
Gary A. Shangold, MD
President-Elect
Hans A. de Haan, MD, PhD, FFPM
Past President
Jonathan Seltzer, MD, MBA
Treasurer
Louis M. Sherwood, MD, MACP
Secretary

Board of Trustees
Charles M. Alexander, MD, CPI
Patricia J. Byrns, MD
Hans A. de Haan, MD, PhD, FFPM
John D. Irvin, MD, PhD
Greg Koski, PhD, MD, CPI
Gary R. Noble, MD, MPH
Stephen M. Oppenheimer, MD, PhD, CPI
Richard G. Pellegrino, MD, PhD
Ihor W. Rak, MD
Scott Segal, MD
Gary A. Shangold, MD
David A. Shapiro, MD, FFPM
Louis M. Sherwood, MD, MACP

Vice Presidents
Charles M. Alexander, MD, CPI
Membership Development
Christopher P. Allen, MD, FFPM
International Relations
Stanley B. Garbus, MD, MPH
Publications
Greg Koski, PhD, MD, CPI
Ethics & Professional Conduct
Barry Miskin, MD, CPI
Patient Advocacy
Thomas J. Newman, MD
Finance
Ihor W. Rak, MD
Strategic Planning and Alliances
Peter H. Rheinstein, MD, JD, MS
AMA Relations
Jonathan Seltzer, MD, MBA
Annual Meeting Planning
David A. Shapiro, MD, FFPM
Public Affairs
Hugh H. Tilson, MD, DrPH
Policy
Ashraf Yousef, MD, PhD, DABT
Education and Professional Development

Anne G. Arella
Executive Director
Joan L. Drucker, MD, CPI
Medical Director

28 May 2004

HHS Task Force on Drug Importation
United States Department of Health & Human Services

To: Members of the Task Force:

As President of the American Academy of Pharmaceutical Physicians, I am writing to state the Academy’s strong position on importation and reimportation of drugs.

Let me first begin by stating that the AAPP is the sole organization in the United States that comprises a membership of Pharmaceutical Physicians (MD or the equivalent degree). Our physicians adhere to the Code of Ethics for the Practice of Pharmaceutical Medicine and they are committed to the mission of enhancing the proficiency of pharmaceutical physicians, promoting the profession of pharmaceutical medicine at all times, protecting the safety and welfare of patients and study subjects.

In 2003, the Academy wrote to the Conferers following a letter in the early summer Speaker Hastert regarding our opposition to HR 2427, the Pharmaceutical Market Access Act. The Academy endorsed and adopted the position of the American Medical Association (AMA) as the official position of the Academy regarding reimportation and shares the AMA’s serious concerns about this issue that may ultimately affect millions of lives.

In keeping with our Statement on Drug Pricing, AAPP is committed to availability of affordable but reliable medicines for all Americans. We believe that despite the allegedly lower prices, medications that are the subject of reimportation or parallel importation cannot be protected or assured for quality or integrity.

The American Academy of Pharmaceutical Physicians contends that the discussion confuses drug safety and drug pricing and that the critical issue, which is not be addressed, is patient safety. The Task Force is well aware that drugs that are distributed in the USA must meet the appropriately high standards of the FDA. While many countries have similar standards to those in the USA, such countries have varying standards for the importation of drugs into their country, making the issue of second- and third-country importation considerably more complex than it first appears. We are not aware of any foreign governments that have expressed a willingness to certify safety of medicine for export to the USA or an other country.

Accordingly, the AAPP continues to contend that we cannot support carte blanche legislation that allows the importation of drugs from other countries. Our stance on change if it can be verified that drugs imported to the USA are subjected to the scrutiny and high standards that the public has the right to expect, as at present. The USA has already developed a reasonable balance between the opposing forces of protecting for intellectual property (which fosters innovation and the discovery of drugs) and the availability of less expensive generic drugs.

American Academy of Pharmaceutical Physicians
2020 G St., NW, Suite 500, Washington, DC 20052

C19
To ignore patient safety in the pursuit of lower drug pricing, we believe, is unethical. It is clear that, at present, the appropriate safeguards cannot be implemented; therefore the Academy opposes the importation of drugs into this country outside the normal distribution channels that are subject to our current high standards of regulation.

Drug pricing issues must be viewed as secondary to those relating to patient product safety.

As "The Voice of Physicians Engaged in Pharmaceutical Medicine," we accept responsibility as experts in the field to educate and inform other healthcare professionals, policy makers, reimbursement agencies, the public, and our patients about the appropriate use of today's drugs, their equitable provision, and their true value. As noted earlier, without question, we are devoted to the protection of the welfare of patients and study subjects.

We strongly urge consideration of the public well being, namely, patient safety, as top priority. Importation or reimportation of drugs without the scrutiny of the FDA puts the public at serious risk because drug quality and integrity cannot be assured.

Thank you for the opportunity to again state AAPP's position on this important issue. Please do not hesitate to have your staff contact our Medical Director, Dr. Jo Drucker in the National Office of AAPP at (919) 355 - 1004, or me if you have questions about our organization, our medical specialty, or our position on this critical topic.

Sincerely,

John D. Irvin, MD, PhD

John D. Irvin, MD, PhD
President & Chairman of the Board

Cc: Members of the AAP Executive Committee